Obesity alters the ovarian proteomic response to zearalenone exposure†

M Estefanía González-Alvarez1, Bailey C McGuire1, Aileen F Keating1

  • 1Department of Animal Science and Interdepartmental Toxicology Graduate Program, Iowa State University, Ames IA, USA.

Insights

Obesity enhances ovarian sensitivity to zearalenone (ZEN), a mycotoxin detrimental to female reproduction. This study suggests obesity adds to ZEN-induced ovotoxicity, impacting reproductive cycles and protein alterations.

Area of Science:

  • Reproductive Toxicology
  • Environmental Health
  • Endocrinology

Background:

  • Zearalenone (ZEN) is a mycotoxin impacting female reproduction.
  • Obesity is linked to altered ovarian function and chemical biotransformation.
  • The interaction between obesity and ZEN's ovarian effects requires investigation.

Purpose of the Study:

  • To investigate if obesity enhances ovarian sensitivity to ZEN exposure.
  • To determine the impact of obesity and ZEN on reproductive parameters and ovarian protein profiles.
  • To elucidate ZEN-induced adverse ovarian modes of action in the context of obesity.

Main Methods:

  • Female mice, lean (KK.Cg-a/a) and obese (KK.Cg-Ay/J), were administered saline or ZEN (40 μg/kg) orally for 15 days.
  • Body weight, organ weights, and estrous cyclicity were monitored.
  • Ovarian protein analysis using LC-MS/MS was performed post-euthanasia.

Main Results:

  • Obese mice exhibited increased body and liver weights.
  • ZEN exposure in obese mice altered estrous cyclicity (increased estrus, shortened metestrus/diestrus).
  • LC-MS/MS revealed alterations in proteins related to chemical metabolism, DNA repair, and reproduction in both lean and obese mice exposed to ZEN.

Conclusions:

  • Obesity appears to exacerbate ZEN-induced ovotoxicity.
  • ZEN exposure, particularly in obese mice, affects reproductive cyclicity.
  • The study identifies specific protein alterations indicative of ZEN's adverse effects on ovarian function, influenced by obesity.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
62
Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
67.4K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
880
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
5.9K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
70
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
51